WG2

To explore the significance of epilipidomics in regulation of biological systems in health and diseases by providing integrative solution for MS-based analysis of modified lipids. To integrate the available information in lipid-centric signalling pathways via networking of researchers working on redox and other types of lipid modifications using different model systems (e.g., cellular models of ferroptosis and apoptosis) (from WG4) and clinical samples (e.g., atherosclerosis, cardiovascular diseases, cancer, aging) (from WG3). This area will be developed in coordination with Society of Free Radical Research and International HNE club.

1. Establishment of pre- and analytical workflows for MS-based detection and identification of modified lipids
2. Exchange of the protocols and definition of SOPs for qualitative and quantitative analysis of different modified lipids, such as including oxylipins, oxysterols, reactive aldehydes, oxidized PLs, TGs, and CEs
3. Benchmarking, further development and optimization of bioinformatics tools for high-throughput identification of modified lipids
4. Collaboration with companies producing lipid standards to initiate commercialization of standard chemically defined modified lipids (including isotopically labelled standards for quantitative epilipidomics)
5. Exploring potential of oxidized lipids as markers for clinical diagnostics (e.g. in oxLDL) and their future translation into design of diagnostics methods/kits together with SMEs involved in the Action
6. Integration of the data on involvement of modified lipids in physiology and pathophysiology by combining results from different models and clinical samples (together with WG4)